Background/Aims: CRIP1 (cysteine-rich intestinal protein 1) has been found in several tumor types; however, its prognostic impact and role in cellular processes, particularly in thyroid carcinoma, are still unclear. Methods: To elucidate the prognostic impact of CRIP1, we analyzed tissues from 58 primary invasive thyroid carcinomas using immunohistochemistry. Western blotting was performed to investigate CRIP1 protein expression in the thyrocyte cell line Nthyori 3-1 and four different thyroid carcinoma cell lines, K1, TPC-1, TT, and SW579. Endogenous expression of CRIP1 was suppressed using a siRNA (si-CRIP1). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to investigate cell viability. Flow cytometric analysis was used to detect cell cycle progression and cell apoptosis. The effects of silencing CRIP1 on cell migration and invasion were detected using the transwell assay. Results: The immunohistochemistry results showed that CRIP1 was overexpressed in thyroid carcinoma. CRIP1 expression was associated with tumor size, TNM stage, and lymphatic metastasis, but not with age, gender, and tumor location. In addition, the expression of CRIP1 in K1, TPC-1, TT, and SW529 cells was higher than that in the Nthy-ori 3-1 cells. The highest expression was observed in the SW579 and TT cells. Furthermore, silencing CRIP1 inhibited the proliferation, migration, and invasion of thyroid carcinoma cell lines SW579 and TT. We also found that silencing CRIP1 induced G1 arrest and apoptosis of thyroid carcinoma cell lines SW579 and TT. Conclusion: In conclusion, CRIP1 acts as an oncogene in the cell proliferation, migration, and invasion processes of thyroid carcinoma. CRIP1 may serve well as an independent prognostic marker with significant predictive power for use in thyroid carcinoma therapy.
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Introduction
Thyroid carcinoma is the most common type of malignant thyroid tumor, which develops from the thyroid epithelial cells [1] . It is mainly divided into four types according to its pathological characteristics, namely papillary carcinoma, follicular adenocarcinoma, medullary thyroid carcinoma, and anaplastic thyroid carcinoma [1] . Although the cause of thyroid cancer is not clear, research advances there have improved understanding of this disease. Regarding thyroid carcinoma, research suggests that morbidity is affected by gender, age, geographical location, race, ionizing radiation exposure, iodine intake, genetics, and sociocultural factors [1] [2] [3] [4] [5] [6] [7] [8] .
Cysteine-rich intestinal protein (CRIP) belongs to the LIM/double zinc-finger protein family, members of which include cysteine-and glycine-rich protein-1 (CSRP1; MIM 123876), rhombotin-1 (RBTN1; MIM 186921), rhombotin-2 (RBTN2; MIM 180385), and rhombotin-3 (RBTN3; MIM 180386) [9] [10] [11] [12] . CRIP1 may be involved in intestinal zinc transport [10, [13] [14] [15] , and is observed to be overexpressed in various types of tumors [16] [17] [18] [19] [20] [21] [22] including breast cancer [20, 21] , osteosarcoma [19] , prostate cancer [17] , pancreatic cancer [16] , and colorectal cancer [23] . Numerous studies have indicated that CRIP1 is an important transcriptional regulation factor during tumor development. In addition, CRIP1 is highly expressed in the intestine and immune cells, and plays an important role in gut immunity. Porcine CRIP1 is activated by Enterococcus faecalis in porcine gastrointestinal epithelial cells [24] .
In the present study, the role of CRIP1 in thyroid carcinoma was investigated. CRIP1 was overexpressed in thyroid carcinoma tissues and cell lines. Furthermore, the relationship between CRIP1 expression and the clinicopathological factors of thyroid carcinoma patients was explored. Lastly, the impact of silencing CRIP1 on cell proliferation, apoptosis, migration, invasion, and cell cycle was assessed. The presented findings provide novel information on the initiation and progression of thyroid carcinoma.
Materials and Methods
Tissues
Thyroid carcinoma tissue was obtained from Henan Provincial People's Hospital. All experiments on human subjects were conducted according to the principles of the Declaration of Helsinki. Written informed consent was obtained from all the enrolled participants. This study was approved by the Ethics Committee of the Henan Provincial People's Hospital.
Immunohistochemical staining
The tissue samples (n = 58) were fixed in buffered formalin (4%), decalcified using ethylenediaminetetraacetic acid (EDTA), if required, and embedded in paraffin. The resulting blocks were cut into 3-µm sections that were transferred to glass slides and subsequently used for immunohistochemistry. To ensure optimum immunoreactivity in tumor samples, immunohistochemistry for CRIP1 was performed according to the routinely used protocols. Immunohistochemical staining was performed on 3 μm-thick sections of the tissue microarrays (TMAs) using an automated stainer (Discovery XT) and a DAB Map kit (Ventana Medical Systems, Tucson, AZ, USA). The CRIP1 primary antibody (AbD Serotec, Oxford, UK) was diluted (1:100), and the staining intensities were scored by two independent observers using a 4-point scale as indicated: 0 (no staining) and from 1+ (light staining) to 3+ (strong staining).
Cell culture
The thyrocyte cell line Nthy-ori 3-1, thyroid papillary carcinoma cell line TPC1, and thyroid carcinoma cell lines K1, SW579, and TT were obtained from the Shanghai Cell Institute Country Cell Bank (Shanghai, China). The SW579 and TT cells were grown in DMEM and F12K media, respectively, with 10% fetal bovine serum (FBS; Gibco BRL, MD) supplemented with 100 U/mL penicillin G and 100 μg/mL streptomycin (Sigma-Aldrich Corp., St. Louis, MO). The cells were maintained at 37 °C in a humidified 5% CO 2 incubator.
RNA interference
Small-interfering RNA (siRNA) oligos for CRIP1 and a general negative control were synthesized and annealed by GenePharma (Shanghai, China). The sequences for CRIP1 siRNA were 5'-GCAACAAGGAGGU-Cellular Physiology and Biochemistry
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GUACUUTT-3' (sense) and 5'-AAGUACACCUCCUUGUUGCTT-3' (antisense). Each siRNA duplex was transfected into the cells using Lipofectamine® 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol.
Quantitative real-time reverse transcription PCR
For quantitative real-time reverse transcription PCR (qRT-PCR), total RNA was extracted from the cells using TRIzol reagent (Ambion®), as described in the manufacturer's protocol [25] . Next, the RNA samples were reverse transcribed into cDNA using the FastQuant RT kit (with gDNase) (Tiangen, China), in a total volume of 20 μL, according to the manufacturer's protocol. Equal amounts of cDNA samples were used as a template for real-time PCR to detect the level of CRIP1 gene expression. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an endogenous reference gene, and each sample was normalized with respect to the GAPDH level. All experiments were performed in duplicates and repeated twice. Results represent the fold change, calculated using the 2 -ΔΔCt method. CRIP1 and GAPDH gene primers were as follows. CRIP1-F: 5'-CCTGCCTGAAGTGCGAGAAAT-3', CRIP1-R: 5'-CCTTTAGGCCCAAACATGGC-3'; GAPDH-F: 5'-TGCACCACCAACTGCTTAGC-3', GAPDH-R: 5'-GGCATGGACTGTGGTCATGAG-3'.
Western blot analysis
Western blot was performed as previously described [25] . Briefly, the proteins were separated by 10% SDS-PAGE and subsequently transferred onto a nitrocellulose membrane (Bio-Rad). After blocking in 5% nonfat milk, the membranes were incubated with either anti-CRIP1 (1:300; Abcam) or the rabbit anti-GAPDH polyclonal primary antibody (1:1000; Abcam). The proteins were visualized with enhanced chemiluminescence reagents (Pierce, Rockford, IL, USA).
Cell viability assay
The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay (MTT) was performed according to the manufacturer's protocol [25] . Briefly, 5, 000 cells/well were plated in triplicate in 96-well plates and allowed to attach overnight. The MTT reagent was prepared at a concentration of 5 mg/mL in PBS. This MTT stock solution, at a dilution of 1:10, was added to each well. The cells were incubated for 4 h and the resulting crystals were dissolved in 100 µL DMSO. The absorbance at 490 nm was measured using a multiwall plate reader.
Apoptosis assay
The apoptosis assay was performed according to the KGI Annexin V-FITC apoptosis detection kit instruction manual. The SW579 and TT cells were digested with trypsin and centrifuged at 1, 000 rpm for 5 min. After collection, the cells were washed twice with PBS and centrifuged at 1, 000 rpm for 5 min. A total of 5 x 10 5 cells were collected and resuspended in 500 µL binding buffer. Subsequently, 5 µL Annexin V-FITC and 5 µL propidium iodide (PI) were added, followed by mixing in the dark at room temperature for 15 min. After 1 h, the apoptotic cells were detected by flow cytometry. The excitation wavelength was 488 nm and the emission wavelength was 530 nm. The green fluorescence of Annexin V-FITC was detected using the FITC channel (FL1) and red fluorescence of PI was detected using the PI channel (FL2 or FL3).
Evaluation of cell cycle
The SW579 and TT cells were digested with trypsin and centrifuged at 1, 000 rpm for 5 min. After collection, the cells were washed twice with PBS, and centrifuged at 1, 000 rpm for 5 min. Next, the cells were suspended in 70% ethanol and incubated overnight. A total of 5 x 10 5 cells were collected and resuspended in 500 µL binding buffer. Subsequently, 5 µL PI was added, followed by mixing in the dark at room temperature for 30 min. After 1 h, the proportion of cells in different phases of the cell cycle was detected by flow cytometry.
Transwell assay
Chambers with matrigel and polycarbonate filters (pore size, 8 µm; Becton Dickinson Labware) were used for the transwell migration assay. Briefly, 24 h after siRNA transfection, the cells were harvested and 5 x 10 4 transfected cells resuspended in 200 µL medium with 0.1% serum/FBS were placed in the upper chamber. The lower chamber was filled with 600 µL of 10% FBS-supplemented medium. After 24 h of incubation and removal of the cells from the upper chamber of the filter with a cotton swab, the cells on the underside were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet in 20% ethanol, and counted in five randomly selected fields under a phase contrast microscope. The migrated or invasive cells were monitored by imaging at 200 × magnification with a LEICA microscope (Darmstadt, Germany). The assays were performed in triplicates.
Statistical analysis
Correlations between CRIP1 and the clinicopathological factors were examined using the Spearman's rank correlation test. Data are represented as mean ± standard deviation (SD), unless otherwise mentioned. The two-tailed Student's t-test was used for analyzing the difference between si-CRIP1 and si-NC groups. A p-value < 0.05 was considered to be statistically significant.
Results
Correlation of CRIP1 expression with clinicopathological parameters
The CRIP1 expression profile in thyroid carcinoma was investigated using immunohistochemical staining. CRIP1 expression was considered to be positive when more than 50% of the tumor cells were immunoreactive for the respective protein (Fig. 1) . In total, CRIP1 expression could be evaluated in 58 tissue samples, and was considered to be positive in 46 tissue samples.
Our data suggested that CRIP1 was overexpressed in thyroid carcinoma ( Fig. 1 and Table 1 ), and higher expression of CRIP1 was associated with tumor size (p = 0.022), TNM stage (p = 0.005), and lymphatic metastasis (p = 0.003) ( Table  1) . There was no statistically significant correlation observed between the expression of CRIP1 and age (p = 0.91), gender (p = 0.358), or tumor location (p = 0.828) ( Table 1) . (Fig. 4A ). This suggested that the silencing of CRIP1 inhibited the proliferation of thyroid carcinoma cells. The data obtained from flow cytometry showed increased apoptosis in the SW579 and TT cells transfected with si-CRIP1 (Fig. 4B ). This suggested that silencing of CRIP1 enhanced apoptosis in the thyroid carcinoma cells. The cell cycle evaluation showed a significant increase in the G1 phase for the SW579 and TT cells transfected with si-CRIP1 (Fig. 4C ). This result suggested that silencing of CRIP1 induced G1 arrest in thyroid carcinoma cells.
Silencing CRIP1 inhibits cell migration and invasion
We investigated the effects of silencing CRIP1 on the migration and invasion of thyroid carcinoma cells using the transwell assay. Decreased migration and invasion abilities were observed for the SW579 and TT cells transfected with si-CRIP1 in comparison with those transfected with si-NC ( Fig. 5A and B) . This result suggested that silencing of CRIP1 inhibited the migration and invasion of thyroid carcinoma cells.
Discussion
In this study, we report that CRIP1 is overexpressed in the thyroid carcinoma tissues and cell lines. Higher expression of CRIP1 was associated with tumor size, TNM stage, and lymphatic metastasis. However, the expression of CRIP1 was not associated with age, gender, or tumor location. In addition, knockdown of CRIP1 expression inhibited the proliferation, migration, and invasion, and induced G1 arrest and apoptosis in the thyroid carcinoma cells.
Several studies have indicated that CRIP1 is involved in few types of cancers, including osteosarcoma [19] , breast cancer [20] , endometrial cancer, [22] and prostate cancer [17] . However, the role of CRIP1 is not conclusively reported in these cancers. A few studies suggest that CRIP1 functions as an oncogene. Lambropoulou et al. showed that higher expression of CRIP1 is associated with shorter survival times in endometrial cancer [22] . Our data supports the oncogenic role of CRIP1. In the present study, CRIP1 was overexpressed in the thyroid carcinoma cells, and its expression was found to be associated with tumor size, TNM stage, and lymphatic metastasis. Moreover, in vitro silencing of CRIP1 inhibited proliferation, migration, and invasion, and induced G1 arrest and apoptosis in the thyroid carcinoma cells. These results suggested that CRIP1 functions as an oncogene in thyroid carcinoma.
In contrast, a few studies indicate that CRIP1 may function as a tumor suppressor. Baumhoer and colleagues showed that CRIP1 expression is correlated with a favorable outcome and less metastasis in patients with osteosarcoma [19] . Ludyga et al. showed that the lack of CRIP1 expression in breast cancer tissues was significantly associated with a poor prognosis for patients [20] . Furthermore, low endogenous CRIP1 levels increased the malignant potential of breast cancer cells in vitro [20] . These results indicate that CRIP1 may act as a tumor suppressor during the proliferation and invasion processes. Therefore, CRIP1 may be an independent prognostic marker with significant predictive power for use in breast cancer therapy [20] .
In conclusion, since the lack of CRIP1 expression in thyroid carcinoma tissues was significantly associated with a poor prognosis for patients and low endogenous CRIP1 levels increased the malignant potential of thyroid carcinoma cells in vitro, we hypothesize that CRIP1 may act as an oncogene during the proliferation and invasion processes. Therefore, CRIP1 could be an independent prognostic marker with significant predictive power for use in thyroid carcinoma therapy.
